Geode Capital Management
UBX

Geode Capital Management’s Unity Biotechnology UBX Stock Holding History

Geode Capital Management’s Portfolio UBX Stock Details UBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-169,025
Closed -$64.2K – 4567
2025
Q2 		$64.2K Buy
169,025
+2,812
+2% +$2.41K ﹤0.01% 4160
2025
Q1 		$173K Buy
166,213
+6,806
+4% +$12.3K ﹤0.01% 3891
2024
Q4 		$156K Sell
159,407
-3,835
-2% -$4.76K ﹤0.01% 3971
2024
Q3 		$240K Buy
163,242
+14,199
+10% +$20.9K ﹤0.01% 3850
2024
Q2 		$201K Buy
149,043
+14,910
+11% +$22.6K ﹤0.01% 3907
2024
Q1 		$220K Buy
134,133
+2,351
+2% +$4.08K ﹤0.01% 3910
2023
Q4 		$254K Hold
131,782
– – ﹤0.01% 3856
2023
Q3 		$316K Buy
131,782
+5,674
+4% +$15K ﹤0.01% 3792
2023
Q2 		$322K Buy
126,108
+3,125
+3% +$8.25K ﹤0.01% 3826
2023
Q1 		$200K Buy
122,983
+31,882
+35% +$128K ﹤0.01% 4050
2022
Q4 		$249K Buy
91,101
+49,004
+116% +$142K ﹤0.01% 3973
2022
Q3 		$166K Buy
42,097
+333
+0.8% +$2.1K ﹤0.01% 4314
2022
Q2 		$235K Sell
41,764
-213
-0.5% -$1.78K ﹤0.01% 4166
2022
Q1 		$470K Buy
41,977
+7,374
+21% +$82.7K ﹤0.01% 3962
2021
Q4 		$505K Buy
34,603
+2,736
+9% +$59.8K ﹤0.01% 4039
2021
Q3 		$956K Buy
31,867
+1,242
+4% +$43.8K ﹤0.01% 3700
2021
Q2 		$1.42M Sell
30,625
-24,887
-45% -$1.2M ﹤0.01% 3430
2021
Q1 		$3.33M Buy
55,512
+8,685
+19% +$592K ﹤0.01% 2985
2020
Q4 		$2.45M Buy
46,827
+1,779
+4% +$85.8K ﹤0.01% 2971
2020
Q3 		$1.56M Sell
45,048
-1,508
-3% -$95.5K ﹤0.01% 3009
2020
Q2 		$4.04M Buy
46,556
+6,389
+16% +$474K ﹤0.01% 2455
2020
Q1 		$2.33M Buy
40,167
+4,532
+13% +$286K ﹤0.01% 2590
2019
Q4 		$2.57M Buy
35,635
+2,795
+9% +$197K ﹤0.01% 2856
2019
Q3 		$2M Buy
32,840
+12,750
+63% +$902K ﹤0.01% 2940
2019
Q2 		$1.91M Buy
20,090
+3,200
+19% +$272K ﹤0.01% 2984
2019
Q1 		$1.37M Buy
16,890
+2,341
+16% +$265K ﹤0.01% 3036
2018
Q4 		$2.37M Buy
14,549
+8,752
+151% +$1.16M ﹤0.01% 2681
2018
Q3 		$944K Buy
5,797
+168
+3% +$27.7K ﹤0.01% 3244
2018
Q2 		$847K Buy
+5,629
New +$823K ﹤0.01% 3249

Other funds holding UBX

Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return
AIP
Ameritas Investment Partners Lincoln, Nebraska $3.25B AUM 28.52% 1-Year Est. Return
AWM
AllSquare Wealth Management Albany, New York $189M AUM 14.89% 1-Year Est. Return

Geode Capital Management's UBX Position: Q3 2025 in Review

Geode Capital Management sold out of Unity Biotechnology (UBX) in Q3 2025, closing a stake of 169,025 shares — an estimated $64.2K sold.

Geode Capital Management first reported a position in UBX in Q2 2018 and held it in 29 quarters. The position peaked at $4.04M in Q2 2020. 6 funds tracked by Wall St. Rank hold UBX as of Q3 2025.

  • Geode Capital Management reported no remaining Unity Biotechnology position as of Q3 2025 after selling out during the quarter.
  • Geode Capital Management sold 169,025 Unity Biotechnology shares in Q3 2025, an estimated $64.2K.
  • Geode Capital Management first reported a position in Unity Biotechnology in Q2 2018 and held it in 29 quarters.
  • Geode Capital Management's Unity Biotechnology position peaked at $4.04M in Q2 2020.
  • 6 funds tracked by Wall St. Rank held Unity Biotechnology as of Q3 2025.

Based on Geode Capital Management's 13F filing for Q3 2025, filed 12 Nov 2025.